Drugs for Gastrointestinal Diseases Practice Questions

Q: Which of the following is NOT a side effect of cimetidine?

Atrophic gastritis. **Explanation:** Cimetidine is a first-generation **H2-receptor antagonist** used to reduce gastric acid secretion. While effective, it is notorious for its significant side-effect profile compared to newer agents like Ranitidine or Famotidine. **Why Atrophic Gastritis is the correct answer:** Atrophic gastritis is characterized by chronic inflammation and thinning of the gastric mucosa, often leading to a loss of parietal cells. It is typically caused by *H. pylori* infection or autoimmune processes. Cimetidine **does not cause** atrophic gastritis; rather, it is used to treat conditions like peptic ulcers and GERD. Long-term use of Proton Pump Inhibitors (PPIs), not H2 blockers, is more commonly associated with concerns regarding gastric atrophy and hypergastrinemia. **Analysis of Incorrect Options:** Cimetidine possesses unique anti-androgenic properties that are not shared by other H2 blockers: * **Impotence & Gynaecomastia (Options A & B):** Cimetidine binds to androgen receptors and inhibits the binding of dihydrotestosterone (DHT). It also inhibits the metabolism of estradiol, leading to increased estrogen levels. This hormonal imbalance results in erectile dysfunction and breast tissue enlargement in men. * **Galactorrhea (Option D):** Cimetidine can increase serum prolactin levels, which may lead to inappropriate milk secretion (galactorrhea) in both men and women. **High-Yield NEET-PG Pearls:** * **Enzyme Inhibition:** Cimetidine is a potent **P450 enzyme inhibitor**. It increases the toxicity of drugs like Warfarin, Phenytoin, and Theophylline. * **BBB Crossing:** Unlike newer H2 blockers, Cimetidine crosses the blood-brain barrier and can cause **mental confusion**, especially in elderly patients with renal impairment. * **Mnemonic:** Remember the "4 Gs" of Cimetidine side effects: **G**ynaecomastia, **G**alactorrhea, **G**uts (CYP inhibition), and **G**uide (Mental confusion).

Q: All of the following are true about prostaglandin E2 except?

It stimulates gastric acid secretion. **Explanation:** Prostaglandins (PGs), specifically **PGE2 and PGI2**, play a vital role in maintaining the integrity of the gastric mucosa. This question tests the understanding of their physiological actions on the stomach. **Why Option C is correct:** PGE2 is a potent **inhibitor** of gastric acid secretion, not a stimulator. It binds to **EP3 receptors** on parietal cells, which are coupled to Gi proteins. This leads to the inhibition of adenylyl cyclase, decreased intracellular cAMP levels, and a subsequent reduction in the activity of the H+/K+ ATPase pump (proton pump). **Analysis of incorrect options:** * **Option A:** PGE2 and PGI2 are indeed the primary prostaglandins synthesized by the gastric mucosa. They are produced via the COX-1 pathway under physiological conditions. * **Option B:** Aspirin and other NSAIDs are non-selective inhibitors of the Cyclooxygenase (COX) enzymes. By inhibiting COX-1, they block the biosynthesis of PGE2, which is the primary mechanism behind NSAID-induced peptic ulcers. * **Option C:** PGE2 promotes mucosal blood flow by causing **vasodilation** of the submucosal microvasculature. This ensures adequate nutrient delivery and removal of back-diffused acid. **NEET-PG High-Yield Pearls:** 1. **Cytoprotective Triad:** PGE2 protects the stomach by: (1) Decreasing acid secretion, (2) Increasing mucus and bicarbonate secretion, and (3) Increasing mucosal blood flow. 2. **Misoprostol:** A synthetic PGE1 analog used clinically to prevent NSAID-induced gastric ulcers. 3. **Side Effects of Misoprostol:** Diarrhea (most common) and uterine contractions (contraindicated in pregnancy as it can cause abortion).

Q: Which of the following does not change the pH of the stomach?

Sucralfate. ### Explanation The correct answer is **A. Sucralfate**. **1. Why Sucralfate is correct:** Sucralfate is a **cytoprotective agent**, not an antacid or an antisecretory drug. It is a complex of aluminum hydroxide and sulfated sucrose. In an **acidic environment (pH < 4)**, it polymerizes into a sticky, viscous paste that binds selectively to the exposed proteins (albumin, fibrinogen) in the ulcer base. This creates a physical barrier against acid, pepsin, and bile. Crucially, sucralfate **does not neutralize gastric acid** nor does it inhibit its secretion; therefore, it does not change the pH of the stomach. **2. Why the other options are incorrect:** * **B & D (H2 Blockers / Ranitidine):** Ranitidine is a competitive antagonist of H2 receptors on parietal cells. By blocking histamine-induced acid secretion, these drugs significantly **increase gastric pH** (make it less acidic) [1]. * **C (Omeprazole):** This is a Proton Pump Inhibitor (PPI) that irreversibly inhibits the $H^+/K^+$-ATPase pump. It is the most potent class of drugs for **increasing gastric pH** [1]. **3. Clinical Pearls for NEET-PG:** * **Activation Requirement:** Sucralfate requires an acidic medium to polymerize. Therefore, it should **not** be given simultaneously with antacids, H2 blockers, or PPIs, as they raise the pH and prevent its activation. * **Side Effects:** The most common side effect of Sucralfate is **constipation** (due to the aluminum content) [1]. * **Drug Interactions:** It can adsorb other drugs (e.g., Tetracycline, Digoxin, Phenytoin); hence, a 2-hour gap is recommended between doses [1]. * **Misoprostol:** Another drug that protects the mucosa but *does* slightly decrease acid secretion (unlike Sucralfate).

Q: What is the primary treatment for NSAID-induced ulcers?

Proton pump inhibitors (PPIs). **Explanation:** The primary mechanism of NSAID-induced ulcers is the inhibition of **COX-1 enzymes**, which leads to a systemic deficiency of cytoprotective prostaglandins ($PGE_2$ and $PGI_2$). This results in decreased bicarbonate/mucus secretion and increased gastric acid production. **1. Why Proton Pump Inhibitors (PPIs) are the Correct Choice:** PPIs (e.g., Omeprazole, Pantoprazole) are the **drugs of choice** for both the treatment and prevention of NSAID-induced ulcers. They are superior to all other agents because they provide profound and sustained inhibition of the final common pathway of acid secretion (the $H^+/K^+$ ATPase pump). This allows the gastric mucosa to heal even if the patient continues to take NSAIDs. **2. Analysis of Incorrect Options:** * **Antacids (A):** These provide only symptomatic relief by neutralizing existing acid. They do not promote ulcer healing or prevent recurrence. * **H2 Blockers (B):** While effective for simple peptic ulcers, they are significantly less effective than PPIs in healing NSAID-induced ulcers, particularly gastric ulcers. * **Misoprostol (C):** This is a $PGE_1$ analog that replaces the prostaglandins inhibited by NSAIDs. While it is highly effective for **prevention**, its clinical use is limited by a high incidence of side effects (diarrhea, abdominal cramps) and the requirement for multiple daily doses. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for treatment:** PPIs. * **DOC for prevention:** PPIs (preferred over Misoprostol due to better tolerability). * **Specific Mechanism:** Misoprostol is the only drug that specifically reverses the underlying prostaglandin deficiency, but it is **not** the first-line treatment. * **Contraindication:** Misoprostol is strictly contraindicated in pregnancy (it is an abortifacient).

Q: Which of the following is NOT an anti-Helicobacter pylori drug?

Ofloxacin. ### Explanation The treatment of *Helicobacter pylori* (H. pylori) infection requires a combination of antibiotics and acid-suppressing agents to ensure eradication and prevent peptic ulcer recurrence. **Why Ofloxacin is the Correct Answer:** Ofloxacin is a second-generation fluoroquinolone. While it has broad-spectrum activity, it is **not** a standard component of first-line or rescue regimens for *H. pylori*. Instead, **Levofloxacin** (a third-generation fluoroquinolone) is the specific drug from this class used in "Levofloxacin-based triple therapy" as a rescue treatment when standard therapies fail. Ofloxacin lacks sufficient clinical evidence for *H. pylori* eradication. **Analysis of Incorrect Options:** * **Clarithromycin (A):** A macrolide that inhibits protein synthesis. It is the backbone of the standard "Clarithromycin-based Triple Therapy." * **Amoxicillin (B):** A penicillin that inhibits cell wall synthesis. It is preferred because *H. pylori* resistance to amoxicillin is rare. * **Metronidazole (C):** A nitroimidazole used particularly in patients with penicillin allergy or in "Bismuth-based Quadruple Therapy." **NEET-PG High-Yield Pearls:** 1. **Standard Triple Therapy (7–14 days):** PPI + Clarithromycin + Amoxicillin (or Metronidazole). 2. **Bismuth Quadruple Therapy:** PPI + Bismuth subsalicylate + Metronidazole + Tetracycline (Used in areas with high clarithromycin resistance). 3. **Pylera:** A 3-in-1 capsule containing Bismuth, Metronidazole, and Tetracycline. 4. **Sequential Therapy:** 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole.

Q: Which of the following is a primary site for the antiemetic action of certain drugs?

Chemoreceptor trigger zone (CTZ). ### Explanation **Correct Answer: A. Chemoreceptor trigger zone (CTZ)** The **Chemoreceptor Trigger Zone (CTZ)** is located in the **Area Postrema** on the floor of the fourth ventricle. It is a primary site for antiemetic action because it lies outside the blood-brain barrier (BBB), allowing it to detect emetogenic toxins or drugs directly from the blood and cerebrospinal fluid. The CTZ is rich in receptors such as **D2, 5-HT3, NK1, and opioid receptors**. Antiemetic drugs (like Ondansetron or Metoclopramide) work by blocking these specific receptors within the CTZ to inhibit the vomiting reflex. **Analysis of Incorrect Options:** * **B. H1 agonist:** This is incorrect because **H1 antagonists** (e.g., Promethazine, Diphenhydramine) are used as antiemetics, particularly for motion sickness. An agonist would likely induce or worsen symptoms. * **C. Dopamine antagonist:** While Dopamine (D2) antagonists (e.g., Domperidone, Haloperidol) are a *class* of antiemetic drugs, the question asks for a **primary site** of action, not a class of drugs. The D2 antagonists exert their effect *at* the CTZ. * **D. Olfactory apparatus:** While strong odors can trigger nausea via higher cortical centers, it is not a primary pharmacological target for antiemetic drugs. **High-Yield Clinical Pearls for NEET-PG:** * **Vomiting Center (VC):** Located in the nucleus tractus solitarius (NTS) of the medulla; it coordinates the physical act of vomiting. * **Motion Sickness:** Primarily involves the **vestibular apparatus** (H1 and M1 receptors). Drug of choice: **Hyoscine (Scopolamine)**. * **Chemotherapy-Induced Nausea and Vomiting (CINV):** The drug of choice for acute prophylaxis is a **5-HT3 antagonist** (e.g., Ondansetron). For highly emetogenic chemo, **Aprepitant** (NK1 antagonist) is added. * **Drug of choice for morning sickness:** Doxylamine + Pyridoxine (Vitamin B6).

Q: What is the drug of choice for an NSAID-induced gastric ulcer?

Misoprostol. **Explanation:** **Mechanism of Action:** NSAIDs induce gastric ulcers primarily by inhibiting the enzyme **Cyclooxygenase-1 (COX-1)**, which leads to a deficiency in endogenous **Prostaglandins (PGE2 and PGI2)**. These prostaglandins are essential for gastric mucosal protection as they stimulate bicarbonate and mucus secretion and maintain mucosal blood flow. **Misoprostol**, a synthetic **PGE1 analogue**, acts as a direct replacement for these lost prostaglandins. It binds to EP3 receptors on parietal cells to inhibit acid secretion and exerts a cytoprotective effect on the gastric mucosa, making it the specific drug of choice for preventing and treating NSAID-induced ulcers. **Analysis of Incorrect Options:** * **Miprinone:** This is likely a distractor or a misspelling of Milrinone (a PDE3 inhibitor used in heart failure). It has no role in acid-peptic disorders. * **Carboprost:** This is a **PGF2α analogue**. While it is a prostaglandin, its clinical use is restricted to obstetrics (postpartum hemorrhage and mid-trimester abortion) due to its potent uterine-contracting properties. * **Miazapine:** Likely a distractor for Mirtazapine (an atypical antidepressant). It does not affect gastric mucosal protection. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** While Misoprostol is the specific DOC based on pathophysiology, in clinical practice, **Proton Pump Inhibitors (PPIs)** are often preferred due to better tolerability. * **Side Effects:** The most common side effect of Misoprostol is **diarrhea** and abdominal cramps. * **Contraindication:** Misoprostol is strictly **contraindicated in pregnancy** (Category X) as it can cause uterine contractions and abortion. * **NSAID of choice in patients with ulcers:** If an NSAID must be used, a selective **COX-2 inhibitor** (e.g., Celecoxib) is preferred as it spares the gastric COX-1.

Q: Erythromycin is given in intestinal hypomotility because?

It binds to motilin receptors. **Explanation:** **Mechanism of Action (Why D is correct):** Erythromycin, a macrolide antibiotic, acts as a **prokinetic agent** by mimicking the action of the endogenous peptide hormone **motilin**. It acts as a non-peptide motilin receptor agonist. These receptors are primarily located on the smooth muscles of the gastrointestinal tract (stomach and duodenum). Binding to these receptors triggers Phase III of the **Migrating Motor Complex (MMC)**, leading to powerful antral contractions that accelerate gastric emptying and intestinal transit. **Analysis of Incorrect Options:** * **A & B:** While Erythromycin is an antibiotic that affects bacterial counts, its prokinetic effect is independent of its antimicrobial properties. In the context of hypomotility, the drug is used for its pharmacological action on smooth muscle receptors, not for its effect on gut flora. * **C:** Erythromycin does not exert its primary GI effect through adenylyl cyclase. Prokinetic agents like 5-HT4 agonists (e.g., Prucalopride) increase cAMP via adenylyl cyclase, but Erythromycin specifically targets motilin receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Use:** It is the drug of choice for **Diabetic Gastroparesis** and is also used in post-operative ileus and to clear the stomach of blood before endoscopy in upper GI bleeds. * **Tachyphylaxis:** A major limitation of Erythromycin as a prokinetic is the rapid development of tolerance (tachyphylaxis) due to down-regulation of motilin receptors. * **Side Effects:** Common GI side effects include abdominal cramps and nausea. It is also a known inhibitor of the **CYP3A4 enzyme**, leading to significant drug interactions.

Q: Which is the most potent proton pump inhibitor?

Lansoprazole. ### Explanation The potency of a Proton Pump Inhibitor (PPI) is determined by its ability to inhibit gastric acid secretion at the lowest dose. Among the listed options, **Lansoprazole** is considered the most potent on a milligram-for-milligram basis in terms of its inhibitory constant ($K_i$) and its ability to achieve rapid symptom relief. #### Why Lansoprazole is Correct: Lansoprazole has a high bioavailability (80-90%) and a rapid onset of action. In comparative pharmacological studies, it demonstrates a higher binding affinity for the $H^+/K^+$ ATPase pump compared to first-generation PPIs like Omeprazole. While clinical efficacy across PPIs is often similar at standard doses, Lansoprazole is technically the most potent in terms of the dose required to achieve significant acid suppression. #### Why Other Options are Incorrect: * **Omeprazole:** The prototype PPI. It is less potent than its newer derivatives and has lower bioavailability (about 40-50%) due to significant first-pass metabolism. * **Esomeprazole:** The S-isomer of omeprazole. While it provides more sustained acid control and higher plasma levels than omeprazole, it is generally considered slightly less potent than Lansoprazole in acute acid suppression studies. * **Rabeprazole:** Known for having the fastest onset of action because it has a higher $pK_a$, allowing it to be activated more quickly in the acidic environment of the parietal cell. However, its absolute potency is lower than Lansoprazole. #### NEET-PG High-Yield Pearls: * **Fastest Acting PPI:** Rabeprazole (due to high $pK_a$). * **Longest Acting PPI:** Tenatoprazole (due to a longer half-life). * **PPI with least drug interactions:** Pantoprazole (least interference with Cytochrome P450). * **Mechanism:** All PPIs are **prodrugs** that require an acidic environment to be converted into the active **sulfenamide** form, which covalently binds to the $H^+/K^+$ ATPase pump (irreversible inhibition).

Q: Ursodeoxycholic acid is a:

Gallstone dissolving drug. **Explanation:** **Ursodeoxycholic acid (UDCA)** is a naturally occurring hydrophilic bile acid that makes up a small fraction of the human bile acid pool. It is primarily used as a **gallstone dissolving drug** (Option C). **Mechanism of Action:** UDCA works by suppressing the synthesis and secretion of cholesterol from the liver and inhibiting its intestinal absorption. This leads to the desaturation of bile with cholesterol, allowing for the gradual dissolution of radiolucent (cholesterol) gallstones. It also has cytoprotective effects in the liver by replacing toxic hydrophobic bile acids. **Analysis of Incorrect Options:** * **Option A (Urinary stone dissolving drug):** These include agents like potassium citrate (for uric acid/cystine stones) or acetazolamide. UDCA has no effect on renal calculi. * **Option B (Thrombolytic drug):** These are "clot busters" like Streptokinase or Alteplase used in MI or stroke. * **Option D (Antifibrinolytic):** These drugs, such as Tranexamic acid, prevent the breakdown of fibrin to control bleeding. **NEET-PG High-Yield Pearls:** 1. **Indications:** UDCA is the drug of choice for **Primary Biliary Cholangitis (PBC)**. It is also used for dissolving small, non-calcified cholesterol gallstones in patients who are unfit for surgery. 2. **Prerequisite for Gallstones:** For UDCA to work, the gallbladder must be **functional** (patent cystic duct) and stones must be **radiolucent** (cholesterol-rich). 3. **Obstetric Use:** It is the preferred treatment for **Intrahepatic Cholestasis of Pregnancy (ICP)** to reduce pruritus and improve liver enzymes.

Question 1

Which of the following is NOT a side effect of cimetidine?

Accepted Answer

Atrophic gastritis

Answer

Impotence

Answer

Gynaecomastia

Answer

Galactorrhea

Question 2

All of the following are true about prostaglandin E2 except?

Accepted Answer

It stimulates gastric acid secretion

Answer

It is the principal prostaglandin synthesized in the stomach

Answer

Its biosynthesis is inhibited by aspirin

Answer

It causes dilatation of submucosa blood vessels

Question 3

Which of the following does not change the pH of the stomach?

Accepted Answer

Sucralfate

Answer

H2 blocker

Answer

Omeprazole

Answer

Ranitidine

Question 4

What is the primary treatment for NSAID-induced ulcers?

Accepted Answer

Proton pump inhibitors (PPIs)

Answer

Antacids

Answer

H2 blockers

Answer

Misoprostol

Question 5

Which of the following is NOT an anti-Helicobacter pylori drug?

Accepted Answer

Ofloxacin

Answer

Clarithromycin

Answer

Amoxicillin

Answer

Metronidazole

Question 6

Which of the following is a primary site for the antiemetic action of certain drugs?

Accepted Answer

Chemoreceptor trigger zone (CTZ)

Answer

H1 agonist

Answer

Dopamine antagonist

Answer

Olfactory apparatus

Question 7

What is the drug of choice for an NSAID-induced gastric ulcer?

Accepted Answer

Misoprostol

Answer

Miprinone

Answer

Carboprost

Answer

Miazapine

Question 8

Erythromycin is given in intestinal hypomotility because?

Accepted Answer

It binds to motilin receptors

Answer

It increases bacterial count

Answer

It decreases bacterial count

Answer

It binds to adenylyl cyclase

Question 9

Which is the most potent proton pump inhibitor?

Accepted Answer

Lansoprazole

Answer

Omeprazole

Answer

Rabeprazole

Answer

Esomeprazole

Question 10

Ursodeoxycholic acid is a:

Accepted Answer

Gallstone dissolving drug

Answer

Urinary stone dissolving drug

Answer

Thrombolytic drug

Answer

Antifibrinolytic

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?